Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on current and emerging immuno-oncology biomarkers to guide selection of optimal cancer treatment across tumor types.

John L. Marshall, MD
Program Director Jamie E. Chaft, MD Scot Niglio, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 24, 2020 Expired: No longer available for credit

Integrating MSI/MMR Testing for GI Cancers (20 mins)

Focus on GU Cancers: Current Clinical Experience With PD-1/PD-L1 Immune Checkpoint Inhibitors (24 mins)

Overview of Biomarker-Selected Immune Checkpoint Blockade in Lung Cancer (22 mins)

Download this short summary slideset of key takeaways from a live CCO Webinar on the use of biomarkers to identify patients who may benefit from immune checkpoint therapy across various solid tumors.

John L. Marshall, MD
Program Director Jamie E. Chaft, MD Scot Niglio, MD Released: July 15, 2020

Download this slideset from John L. Marshall, MD to review key data on the use of MSI/MMR testing and immunotherapy for patients with GI cancers.

John L. Marshall, MD
Program Director Released: July 9, 2020

Download this slideset from Scot Niglio, MD to see an overview of how IO biomarkers are currently used for patients with GU cancers, with key data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.

Scot Niglio, MD Released: July 9, 2020

Download this slideset from Jamie E. Chaft, MD to see a summary of key data on the use of immune checkpoint inhibitor therapy for patients with lung cancer, with information on when IO biomarkers are needed to select optimal therapy.

Jamie E. Chaft, MD Released: July 9, 2020

Listen to John L. Marshall, MD; Jamie E. Chaft, MD; and Scot Niglio, MD, answer audience questions from a live CCO Webinar on biomarker testing and the impact on immunotherapy treatment for diverse solid tumors including the latest on PD-L1, dMMR/MSI-high, tumor mutation burden, and other emerging biomarkers.

John L. Marshall, MD
Program Director Jamie E. Chaft, MD Scot Niglio, MD Released: August 10, 2020